BNTX

Moderna Inc. Chief Executive Stéphane Bancel pushed back against criticism of the company’s pricing plans for its Covid-19 vaccine at Monday’s Wall Street Journal Health Forum.  U.S. politicians including Sens. Bernie Sanders (I., Vt.), Elizabeth Warren (D., Mass.) and Peter Welch (D., Vt.) have questioned the company’s strategy around commercial pricing, which could be unveiled in the coming months. Moderna received funding…

Pharmaceutical companies are grappling with the arrival in the U.S. of sweeping new legislation meant to blunt drug prices. The impact in 2023 may actually be higher drug prices. President Biden last year signed into law the bill dubbed the Inflation Reduction Act, empowering Medicare, the country’s biggest buyer of prescription drugs, to negotiate how much it pays for certain high-price therapies. Another provision set a cap on price increases that requires drugmakers to pay Medicare rebates on treatments whose prices…

Moderna Inc. said it is considering pricing its Covid-19 vaccine in a range of $110 to $130 per dose in the U.S. when it shifts from government contracting to commercial distribution of the shots. The range is similar to the one Pfizer Inc. said in October it was considering for the Covid-19 vaccine it developed with BioNTech SE. “I would think this type of pricing is consistent with…

A vial of the Pfizer-BioNTech Covid-19 vaccine. Photo: HANNAH BEIER/REUTERS China agreed to…

Rival drugmakers are seeking to upend Pfizer Inc.’s dominance of the $7 billion worldwide market for pneumonia vaccines, launching what is shaping up to be one of the industry’s fiercest battles. Merck & Co. has already introduced a new competitor to Pfizer’s Prevnar vaccine franchise, while GSK PLC and Vaxcyte Inc. are among companies developing shots that aim to win sales by protecting against even…

Pfizer Inc. gave some details about its plans to sell the Covid-19 vaccine it developed with BioNTech SE on the commercial market in the U.S., saying it expects to price the shot at $110 to $130 per dose for adults.  The drugmaker is still negotiating with health insurers, but anticipates the discussions will lead to a list price in the range, Angela Lukin, a Pfizer official, said Thursday. She said the company…

The retooled Covid-19 booster from Pfizer Inc. and BioNTech SE generated a strong immune response against the Omicron substrains BA.4 and BA.5, the companies said. The data, which the companies reported in a news release Thursday, offer the first window into how the new shots rolling out across the U.S. perform. An early look at data from ongoing testing in people at least 18 years old found the booster generated…

AstraZeneca PLC produced one of the world’s most widely used Covid-19 vaccines. As demand for the shot ebbs, the company is betting on tackling breast cancer and a different respiratory virus. Now the company is reducing production of its vaccine, while lining up successors to some blockbusters that have helped propel the company’s growth in recent years but are nearing the end of their patent protection. “The vaccine and Evusheld were important in the last two years,” said…

Pfizer Inc. and BioNTech SE asked U.S. health regulators to clear use of their updated Covid-19 booster in children 5 years to 11 years.The companies made the request on Monday as retooled shots for people 12 and older roll out across the country. Health authorities people to get the shots to increase protection against the virus in case of fall or winter surges. A decision by the Food and Drug Administration on the request could come before the end of the…

Some U.S. pharmacies and other vaccine providers are offering the new Covid-19 booster shot only from Pfizer Inc. and BioNTech SE, after a manufacturing-quality problem at a contract manufacturer caused a shortage of Moderna Inc.’s new booster shot.In recent days, federal officials have advised state officials there is a limited supply of Moderna’s updated booster shots, said Marcus Plescia, chief…